Glioblastoma multiforme imaging: The role of nuclear medicine

Current Radiopharmaceuticals

Volumn 5, Issue 4, 2012, Pages 308-313

  Alexiou, George A ^a   Tsiouris, Spyridon ^a   Voulgaris, Spyridon ^a   Kyritsis, Athanasios P ^a   Fotopoulos, Andreas D ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Chemotherapy; Glioblastoma multiforme; Nuclear medicine; PET; Radiotherapy; SPECT; Surgery

Indexed keywords

TEMOZOLOMIDE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; INCIDENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR NECROSIS; TUMOR RECURRENCE;

BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GLIOBLASTOMA; HUMANS; NECROSIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION INJURIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84862016653     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011205040308     Document Type: Article

References (53)

1. Liu, Y.; Shete, S.; Etzel, C.J.; Scheurer, M.; Alexiou, G.; Armstrong, G.; Tsavachidis, S.; Liang F.W.; Gilbert, M.; Aldape, K.; Armstrong, T.; Houlston, R.; Hosking, F.; Robertson, L.; Xiao, Y.; Wiencke, J.; Wrensch, M.; Andersson, U.; Melin, B.S.; Bondy, M. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J. Clin. Oncol., 2010, 28, 2467-2474.
2. Baldi, I.; Huchet, A.; Bauchet, L.; Loiseau, H. [Epidemiology of glioblastoma]. Neurochirurgie, 2010, 56, 433-440.
3. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N. Engl. J. Med., 2005, 352, 987-996.
4. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.;, Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, 10, 459-466.
5. Sant, M.; Minicozzi, P.; Lagorio, S.; Johannesen, T.B.; Marcos-Gragera, R.; Francisci, S.; The EUROCARE Working Group. Survival of european patients with central nervous system tumors. Int. J. Cancer, 2011, doi: 10.1002/ijc.26335.
6. Ang, C.; Guiot, M.C.; Ramanakumar, A.V.; Roberge, D.; Kavan, P. Clinical significance of molecular biomarkers in glioblastoma. Can. J. Neurol. Sci., 2010, 37, 625-630.
7. Alexiou, G.A.; Voulgaris, S. The role of the PTEN gene in malignant gliomas. Neurol. Neurochir. Pol., 2010, 44, 80-86.
8. Alexiou, G.A.; Tsiouris, S.; Kyritsis, A.P.; Argyropoulou, M.; Fotopoulos, A. Assessment of gliomas proliferation by imaging modalities. J. Clin. Neurosci., 2010, 17, 1233-1238.
9. Fukumoto, M. Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin. Ann. Nucl. Med., 2004, 18, 79-95.
10. Chen, W. Clinical applications of PET in brain tumors. J. Nucl. Med., 2007, 48, 1468-1481.
11. QuiHnes-Hinojosa, A.; Sanai, N.; Smith, J.S.; McDermott, M.W. Techniques to assess the proliferative potential of brain tumors. J. Neurooncol., 2005, 74, 19-30.
12. Oriuchi, N.; Tamura, M.; Shibazaki, T. Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities. J. Nucl. Med., 1993, 34, 2085-2089.
13. Ishibashi, M.; Taguchi, A.; Sugita, Y. Thallium-201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. J. Nucl. Med.; 1995, 36, 2201-2206.
14. Gungor, F.; Bezircioglu, H.; Guven, G. Correlation of thallium-201 uptake with proliferating cell nuclear antigen in brain tumours. Nucl. Med. Commun., 2000, 21, 803-810.
15. Asano, K.; Takeda, T.; Nakano, T.; Ohkuma, H. Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors. Brain Tumor Pathol., 2010, 27, 1-6.
16. Nagamachi, S.; Jinnouchi, S.; Nabeshima, K. The correlation between 99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma-a comparative study with 201Tl. Neuroradiology, 2001, 43, 1023-1030.
17. Ak, I.; Gulbas, Z.; Altinel, F.; Vardareli, E. Tc-99m MIBI uptake and its relation to the proliferative potential of brain tumors. Clin. Nucl. Med., 2003, 28, 29-33.
18. Alexiou, G.A.; Tsiouris, S.; Goussia, A.; Polyzoidis, K.S.; Kyritsis, A.P.; Fotopoulos, A.D. Evaluation of glioma proliferation by 99mTc-Tetrofosmin. NeuroOncol., 2008, 10, 104-105.
19. Alexiou, G.A.; Tsiouris, S.; Vartholomatos, G.; Fotakopoulos, G.; Papadopoulos, A.; Kyritsis, A.P.; Voulgaris, S.; Fotopoulos, A.D. Correlation of glioma proliferation assessed by flow cytometry with (99m)Tc-Tetrofosmin SPECT uptake. Clin. Neurol. Neurosurg., 2009, 111, 808-811.
20. Kato, T.; Shinoda, J.; Nakayama, N. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. Am. J. Neuroradiol., 2008, 29, 1176-1182.
21. Hatakeyama, T.; Kawai, N.; Nishiyama, Y.; Yamamoto, Y.; Sasakawa, Y.; Ichikawa, T.; Tamiya, T. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 2009-2017.
22. Chen, W.; Cloughesy, T.; Kamdar, N.; Satyamurthy, N.; Bergsneider, M.; Liau, L.; Mischel, P.; Czernin, J.; Phelps, M.E.; Silverman, D.H. Imaging proliferation in brain tumors with 18FFLT PET: comparison with 18F-FDG. J. Nucl. Med., 2005, 46, 945-952.
23. Fueger, B.J.; Czernin, J.; Cloughesy, T.; Silverman, D.H.; Geist, C.L.; Walter, M.A.; Schiepers, C.; Nghiemphu, P.; Lai, A.; Phelps, M.E.; Chen, W. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J. Nucl. Med., 2010, 51, 1532-1538.
24. Alexiou, G.A.; Tsiouris, S.; Kyritsis, A.P.; Voulgaris, S.; Argyropoulou, M.I.; Fotopoulos, A.D. Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J. Neurooncol., 2009, 95, 1-11.
25. Alexiou, G.; Tsiouris, S.; Fotopoulos, A. [Single-photon emission computed tomography in the evaluation of brain tumors and the diagnosis of relapse vs radiation necrosis]. Hell. J. Nucl. Med., 2007, 10, 205-208.
26. Chamberlain, M.C.; Glantz, M.J.; Chalmers, L.; Van Horn, A.; Sloan, A.E. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J. Neurooncol., 2007, 82, 81-83.
27. Yoshii, Y.; Satou, M.; Yamamoto, T. The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment. Eur. J. Nucl. Med., 1993, 20, 39-45.
28. Vos, M.J.; Tony, B.N.; Hoekstra, O.S.; Postma, T.J.; Heimans, J.J.; Hooft, L. Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in the detection of recurrent glioma. Nucl. Med. Commun., 2007, 28, 431-439.
29. Le Jeune, F.P.; Dubois, F.; Blond, S.; Steinling, M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J. Neurooncol., 2006, 77, 177-183.
30. Alexiou, G.A.; Fotopoulos, A.D.; Papadopoulos, A.; Kyritsis, A.P.; Polyzoidis, K.S.; Tsiouris, S. Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study. Ann. Nucl. Med., 2007, 21, 293-298.
31. Barai, S.; Bandopadhayaya, G.P.; Julka, P.K.; Haloi, A.K.; Seith, A.; Malhotra, A. Evaluation of single photon emission computerised tomography (SPECT) using Tc99m-tetrofosmin as a diagnostic modality for recurrent posterior fossa tumours. J. Postgrad. Med., 2003, 49, 316-320.
32. Alexiou, G.A.; Tsiouris, S.; Voulgaris, S.; Doukas, M.; Goussia, A.; Kyritsis, A.P.; Polyzoidis, K.S.; Fotopoulos, A.D. Brain scintigraphy with 99mTc-tetrofosmin for the differential diagnosis of a posterior fossa tumor. Hell. J. Nucl. Med., 2008, 11, 114-117.
33. Santra, A.; Kumar, R.; Sharma, P.; Bal, C.; Kumar, A.; Julka, P.K.; Malhotra, A. F-18 FDG ET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J. Radiol., 2011, doi: 10.1016/j.ejrad.2011.01.080.
34. Santra, A.; Kumar, R.; Sharma, P.; Bal, C.; Julka, P.K.; Malhotra, A. Detection of recurrence in glioma: a comparative prospective study between Tc-99m GHA SPECT and F-18 FDG PET/CT. Clin. Nucl. Med., 2011, 36, 650-655.
35. Ricci, P.E.; Karis, J.P.; Heiserman, J.E. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am. J. Neuroradiol., 1998, 19, 407-413.
36. Olivero, W.C.; Dulebohn, S.C.; Lister, J.R. The use of PET in evaluating patients with primary brain tumors: is it useful? J. Neurol. Neurosurg. Psychiatry, 1995, 58, 250-252.
37. Terakawa, Y.; Tsuyuguchi, N.; Iwai, Y.; Yamanaka, K.; Higashiyama, S.; Takami, T.; Ohata, K. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J. Nucl. Med., 2008, 49, 694-699.
38. Ogawa, T.; Kanno, I.; Shishido, F.; Inugami, A.; Higano, S.; Fujita, H.; Murakami, M.; Uemura, K.; Yasui, N.; Mineura, K. et al. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol., 1991, 32, 197-202.
39. Spence, A.M.; Muzi, M.; Link, J.M.; O'Sullivan, F.; Eary, J.F.; Hoffman, J.M.; Shankar, L.K.; Krohn, K.A. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol. Imaging. Biol., 2009, 11, 343-355.
40. Chen, W.; Silverman, D.H.; Delaloye, S. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J. Nucl. Med., 2006, 47, 904-911.
41. rd. Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiformee: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy. J. Neurosurg., 1998, 89, 60-68.
42. Weber, W.A.; Dick, S.; Reidl, G.; Dzewas, B.; Busch, R.; Feldmann, H.J.; Molls, M.; Lumenta, C.B.; Schwaiger, M.; Grosu, A.L. Correlation between postoperative 3-[(123)I]iodo-L-alphamethyltyrosine uptake and survival in patients with gliomas. J. Nucl. Med., 2001, 42, 1144-1150.
43. Alexiou, G.A.; Tsiouris, S.; Kyritsis, A.P.; Fotakopoulos, G.; Goussia, A.; Voulgaris, S.; Fotopoulos, A.D. The value of 99mTctetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiformee. J. Nucl. Med., 2010, 51, 1923-1926.
44. Di Chiro, G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest. Radiol., 1986, 22, 360-371.
45. Padma, M.V.; Said, S.; Jacobs, M.; Hwang, D.R.; Dunigan, K.; Satter, M.; Christian, B.; Ruppert, J.; Bernstein, T.; Kraus, G.; Mantil, J.C. Prediction of pathology and survival by FDG PET in gliomas. J. Neurooncol., 2003, 64, 227-237.
46. Pardo, F.S.; Aronen, H.J.; Fitzek, M.; Kennedy, D.N.; Efird, J.; Rosen, B.R.; Fischman, A.J. Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res., 2004, 24, 2359-2365.
47. Pötzi, C.; Becherer, A.; Marosi, C.; Karanikas, G.; Szabo, M.; Dudczak, R.; Kletter, K.; Asenbaum, S. [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiformee. J. Neurooncol., 2007, 84, 305-314.
48. Santra, A.; Kumar, R.; Sharma, P.; Bal, C.; Julka, P.K.; Malhotra, A. F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study. Neuroradiology, 2011, doi: 10.1007/s00234-011-0898-3.
49. Bleichner-Perez, S.; Le Jeune, F.; Dubois, F.; Steinling, M. 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. Nucl. Med. Commun., 2007, 28, 888-894.
50. Hutterer, M.; Nowosielski, M.; Putzer, D.; Waitz, D.; Tinkhauser, G.; Kostron, H.; Muigg, A.; Virgolini, I.J.; Staffen, W.; Trinka, E.; Gotwald, T.; Jacobs, A.H.; Stockhammer, G. O-(2-18Ffluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J. Nucl. Med., 2011, 52, 856-864.
51. Piroth, M.D.; Pinkawa, M.; Holy, R.; Klotz, J.; Nussen, S.; Stoffels, G.; Coenen, H.H.; Kaiser, H.J.; Langen, K.J.; Eble, M.J. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiformee. Int. J. Radiat. Oncol. Biol. Phys., 2011, 80, 176-184.
52. Battle, M.R.; Goggi, J.L.; Allen, L.; Barnett, J.; Morrison, M.S. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled Vbeta3-integrin and V beta5-integrin imaging agent. J. Nucl. Med., 2011, 52, 424-430.
53. Dhermain, F.G.; Hau, P.; Lanfermann, H.; Jacobs, A.H.; van den Bent, M.J. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol., 2010, 9, 906-920.